Nitecki R, Woodward T, Rauh-Hain A. Fertility-sparing treatment for early-stage cervical, ovarian, and endometrial malignancies. Obstet Gynecol 2020;136.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 1 of 2
Appendix 1. Summary of Major Randomized Trials Using GnRH Agonists Author Name of Trial Disease
Site
Type of GnRH Agonist
No. in Final Analysis (intervention vs. control)
Primary Endpoint
Outcome (intervention vs. control)
Pregnancy Rates
(intervention vs. control) Moore
(2015)100
POEMS Breast
cancer
Goserelin (3.6 mg SC 1 week before
chemotherapy, then every 4 weeks during chemotherapy)
66 vs. 69 Ovarian failure at 2 years (absence of menses and FSH in the postmenopausal range)
8% vs. 22% 21% vs. 11%
Munster (2012)101
NA Breast
cancer
Triptorelin (3.75 mg IM at least 1 week before chemotherapy every 28-30 days)
26 vs. 21 Preservation of ovarian function (number of patients with uninterrupted or restored menses)
90% vs. 88% 2 in control group
Leonard (2017)102
OPTION Breast cancer
Goserelin (3.6 mg at least 1week, and preferably 2 weeks, prior to the start of chemotherapy every 3–4 weeks)
95 vs. 107 Premature ovarian insufficiency (amenorrhea between 12 and 24 months after randomization)
22% vs. 38% 9 vs. 6
Elgindy (2013)103
NA Breast
cancer
Cetrorelix (0.25 mg daily until estradiol downregulation) + triptorelin 3.75 mg every 4 weeks during chemotherapy)
50 vs. 50 Resumption of menstruation at 12 months after end of
chemotherapy
80% vs. 80% 2 in
intervention, 1 in control
Nitecki R, Woodward T, Rauh-Hain A. Fertility-sparing treatment for early-stage cervical, ovarian, and endometrial malignancies. Obstet Gynecol 2020;136.
The authors provided this information as a supplement to their article.
©2020 American College of Obstetricians and Gynecologists. Page 2 of 2
Lambertini (2015)104
PROMISE- GIM6
Breast cancer
Triptorelin (3.75 mg IM 1 week before chemotherapy and then every 4 weeks during chemotherapy)
148 vs. 133 Menstrual resumption
72.6% vs. 64% 5.4% vs.
2.2%
Gerber (2011)105
NA Breast
cancer
Goserelin (3.5 SC 2 weeks before chemotherapy and every 4 weeks thereafter)
30 vs. 30 Reappearance of normal ovarian function (2 consecutive menstrual periods within 21 to 35 days at 6 months after end of chemotherapy)
70% vs 56.7% NA
Demeestere (2016)60
NCT01160315 Lymphoma Triptorelin (11.25 mg every 12 weeks)
32 vs. 35 Premature
ovarian failure (at least one FSH value of 40 IU/L after 2 years of follow-up)
19.4% vs 25% 53.1% vs.
42.8%
GnRH, gonadotropin-releasing hormone; SC, subcutaneous; FSH, follicle-stimulating hormone; IM, intramuscular.
